150 related articles for article (PubMed ID: 9137907)
21. Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration.
González AM; Berciano J; Figols J; Pazos A; Pascual J
Brain Res; 2000 Jan; 852(1):228-32. PubMed ID: 10661519
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo effects of cocaine and selected local anesthetics on the dopamine transporter.
Woodward JJ; Compton DM; Balster RL; Martin BR
Eur J Pharmacol; 1995 Apr; 277(1):7-13. PubMed ID: 7635175
[TBL] [Abstract][Full Text] [Related]
23. The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons.
Hurd YL; Pristupa ZB; Herman MM; Niznik HB; Kleinman JE
Neuroscience; 1994 Nov; 63(2):357-62. PubMed ID: 7891851
[TBL] [Abstract][Full Text] [Related]
24. Structural domains of chimeric dopamine-noradrenaline human transporters involved in the Na(+)- and Cl(-)-dependence of dopamine transport.
Syringas M; Janin F; Mezghanni S; Giros B; Costentin J; Bonnet JJ
Mol Pharmacol; 2000 Dec; 58(6):1404-11. PubMed ID: 11093780
[TBL] [Abstract][Full Text] [Related]
25. Rat mesencephalic neuronal cells cultured for different periods as a model of dopamine transporter ontogenesis.
Valchár M; Hanbauer I
Mol Neurobiol; 1995; 11(1-3):111-9. PubMed ID: 8561956
[TBL] [Abstract][Full Text] [Related]
26. In vivo regulation of central nervous system progesterone receptors: cocaine induces steroid-dependent behavior through dopamine transporter modulation of D5 receptors in rats.
Apostolakis EM; Garai J; Clark JH; O'Malley BW
Mol Endocrinol; 1996 Dec; 10(12):1595-604. PubMed ID: 8961269
[TBL] [Abstract][Full Text] [Related]
27. Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter.
Matsubara K; Senda T; Uezono T; Fukushima S; Ohta S; Igarashi K; Naoi M; Yamashita Y; Ohtaki K; Hayase N; Akutsu S; Kimura K
Eur J Pharmacol; 1998 May; 348(1):77-84. PubMed ID: 9650834
[TBL] [Abstract][Full Text] [Related]
28. Arachidonic acid stimulates a novel cocaine-sensitive cation conductance associated with the human dopamine transporter.
Ingram SL; Amara SG
J Neurosci; 2000 Jan; 20(2):550-7. PubMed ID: 10632584
[TBL] [Abstract][Full Text] [Related]
29. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants.
Sonders MS; Zhu SJ; Zahniser NR; Kavanaugh MP; Amara SG
J Neurosci; 1997 Feb; 17(3):960-74. PubMed ID: 8994051
[TBL] [Abstract][Full Text] [Related]
30. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine.
Woolverton WL; Wang Z
Eur J Pharmacol; 2004 Feb; 486(3):251-7. PubMed ID: 14985046
[TBL] [Abstract][Full Text] [Related]
31. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?
Xu C; Reith ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):1340-8. PubMed ID: 8819521
[TBL] [Abstract][Full Text] [Related]
32. A cognate dopamine transporter-like activity endogenously expressed in a COS-7 kidney-derived cell line.
Sugamori KS; Lee FJ; Pristupa ZB; Niznik HB
FEBS Lett; 1999 May; 451(2):169-74. PubMed ID: 10371159
[TBL] [Abstract][Full Text] [Related]
33. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease.
Paus S; Seeger G; Brecht HM; Köster J; El-Faddagh M; Nöthen MM; Klockgether T; Wüllner U
Mov Disord; 2004 Jun; 19(6):705-7. PubMed ID: 15197713
[No Abstract] [Full Text] [Related]
34. [The dopamine transporter: characterization and physiopathologic implications].
Thibaut F; Vaugeois JM; Petit M
Encephale; 1995; 21(6):445-51. PubMed ID: 8674469
[TBL] [Abstract][Full Text] [Related]
35. Dopamine transporters participate in the physiological regulation of prolactin.
Demaria JE; Nagy GM; Lerant AA; Fekete MI; Levenson CW; Freeman ME
Endocrinology; 2000 Jan; 141(1):366-74. PubMed ID: 10614659
[TBL] [Abstract][Full Text] [Related]
36. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.
Lin Z; Wang W; Uhl GR
Mol Pharmacol; 2000 Dec; 58(6):1581-92. PubMed ID: 11093799
[TBL] [Abstract][Full Text] [Related]
37. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.
Yang YK; Yu L; Yeh TL; Chiu NT; Chen PS; Lee IH;
Am J Psychiatry; 2004 Aug; 161(8):1496-8. PubMed ID: 15285982
[TBL] [Abstract][Full Text] [Related]
38. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
39. Tc-99m-labeled tropanes as dopamine transporter imaging agents.
Meegalla S; Plössl K; Kung MP; Chumpradit S; Stevenson DA; Frederick D; Kung HF
Bioconjug Chem; 1996; 7(4):421-9. PubMed ID: 8853455
[TBL] [Abstract][Full Text] [Related]
40. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes.
Cowell RM; Kantor L; Hewlett GH; Frey KA; Gnegy ME
Eur J Pharmacol; 2000 Feb; 389(1):59-65. PubMed ID: 10686296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
